VKTX - FDA Decision For Intercept's NASH Drug Ocaliva Delayed; Opportunity Presents Itself
This past week, Intercept Pharmaceuticals (ICPT) was notified by the FDA that its PDUFA date for Ocaliva to treat patients with NASH would be delayed to June 26, 2020. However, any potential weakness or downtrend in the stock in the coming months should be viewed as a great buying opportunity. That's because the company had already received prior notice from FDA that it would schedule an advisory committee meeting to review Ocaliva for NASH first in April. Specifically, the advisory committee meeting is set for April 22, 2020. I believe that Ocaliva will